The current PE ratio of ARWR cannot be calculated, as the latest EPS of -$1.7 is negative. Arrowhead Pharmaceuticals's last PE ratio on record was 287.7 in March 2020.
The mean historical PE ratio of Arrowhead Pharmaceuticals over the last five years is 145.59. Looking back at the last five years, ARWR's PE ratio peaked in the Mar 2020 quarter at 287.7, with a price of $28.77 and an EPS of $0.1. The Sep 2019 quarter marked the lowest point at 39.14, with a price of $28.18 and an EPS of $0.72.
|Stock name||PE ratio||Market cap|
|JNJ Johnson & Johnson||31.04||$402.53B|
|MRNA Moderna Inc||32.6||$38.47B|
|LGND Ligand Pharmaceuticals Inc||37.27||$1.02B|
|ALNY Alnylam Pharmaceuticals Inc||N/A||$21.77B|
|INO Inovio Pharmaceuticals Inc||N/A||$101.44M|
|NANX NANOPHASE TECHNOLOGIES Corp||N/A||$43.39M|
|ARWR Arrowhead Pharmaceuticals Inc||N/A||$2.72B|
The current price to earnings ratio of ARWR cannot be determined, as its EPS of -$1.7 is negative.
As an average over the last 5 years, ARWR stock has a PE ratio of 145.59.
The highest quarterly PE ratio in the last five years has been 287.7 and it was in the Mar 2020 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.